Serial in vivo imaging of the targeted migration of human HSV-TK-transduced antigen-specific lymphocytes

New technologies are needed to characterize the migration, survival, and function of antigen-specific T cells in vivo. Here, we demonstrate that Epstein-Barr virus (EBV)–specific T cells transduced with vectors encoding herpes simplex virus-1 thymidine kinase (HSV-TK) selectively accumulate radiolabeled 2′-fluoro-2′-deoxy-1-β-D-arabinofuranosyl-5-iodouracil (FIAU). After adoptive transfer, HSV-TK+ T cells labeled in vitro or in vivo with [131I]FIAU or [124I]FIAU can be noninvasively tracked in SCID mice bearing human tumor xenografts by serial images obtained by scintigraphy or positron emission tomography (PET), respectively. These T cells selectively accumulate in EBV+ tumors expressing the T cells' restricting HLA allele but not in EBV− or HLA-mismatched tumors. The concentrations of transduced T cells detected in tumors and tissues are closely correlated with the concentrations of label retained at each site. Radiolabeled transduced T cells retain their capacity to eliminate targeted tumors selectively. This technique for imaging the migration of ex vivo–transduced antigen-specific T cells in vivo is informative, nontoxic, and potentially applicable to humans.

[1]  E. Lance,et al.  The distribution of chromium 51-labelled lymphoid cells in the mouse. A survey of anatomical compartments. , 1970, Cellular immunology.

[2]  E. Lance,et al.  Lymphocyte trapping in tolerant mice. , 1971, Nature: New biology.

[3]  R. Bourey,et al.  Technetium-99m labeling of human monocytes for chemotactic studies. , 1976, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[4]  R. Barth,et al.  Organ distribution of 99mTc- and 51Cr-labeled autologous peripheral blood lymphocytes in rabbits. , 1977, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[5]  M. Thakur,et al.  An experimental comparison of radioactive labels with potential application to lymphocyte migration studies in patients. , 1977, Clinical and experimental immunology.

[6]  L. Shepp,et al.  Maximum Likelihood Reconstruction for Emission Tomography , 1983, IEEE Transactions on Medical Imaging.

[7]  L. Shepp,et al.  Maximum Likelihood Reconstruction for Emission Tomography , 1983, IEEE Transactions on Medical Imaging.

[8]  R. Schelper,et al.  Monocytes Become Macrophages; They Do Not Become Microglia: A Light and Electron Microscopic Autoradiographic Study Using 125‐lododeoxyuridine , 1986, Journal of neuropathology and experimental neurology.

[9]  R. P. Spencer,et al.  Utilization of tumour-sensitized ('educated') and radiolabelled lymphocytes for tumour localization. , 1988, Nuclear medicine communications.

[10]  R. P. Spencer,et al.  Imaging pattern of previously in vitro sensitized and interleukin-2 expanded autologous lymphocytes in human cancer. , 1988, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.

[11]  S M Larson,et al.  Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  W. Wilmanns,et al.  Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. , 1990, Blood.

[13]  S. Riddell,et al.  Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. , 1992, Science.

[14]  F Daghighian,et al.  Imaging of brain tumor proliferative activity with iodine-131-iododeoxyuridine. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[15]  M. Ladanyi,et al.  Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. , 1994, The New England journal of medicine.

[16]  H. Heslop,et al.  Donor T cells to treat EBV-associated lymphoma. , 1994, The New England journal of medicine.

[17]  R. Krance,et al.  Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation , 1995, The Lancet.

[18]  R. Blasberg,et al.  Imaging the expression of transfected genes in vivo. , 1995, Cancer research.

[19]  M. Ladanyi,et al.  Human Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes home preferentially to and induce selective regressions of autologous EBV- induced B cell lymphoproliferations in xenografted C.B-17 scid/scid mice [published erratum appears in J Exp Med 1996 Sep 1;184(3):1199] , 1996, The Journal of experimental medicine.

[20]  P. Steinherz,et al.  Growth pattern and clinical correlation of subcutaneously inoculated human primary acute leukemias in severe combined immunodeficiency mice. , 1996, Blood.

[21]  R G Blasberg,et al.  Noninvasive imaging of herpes virus thymidine kinase gene transfer and expression: a potential method for monitoring clinical gene therapy. , 1996, Cancer research.

[22]  S M Larson,et al.  Triumph over mischance: a role for nuclear medicine in gene therapy. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[23]  M. Sadelain,et al.  The internal ribosomal entry site of the encephalomyocarditis virus enables reliable coexpression of two transgenes in human primary T lymphocytes , 1997, Gene Therapy.

[24]  C. Bordignon,et al.  HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. , 1997, Science.

[25]  Robert H. Collins,et al.  Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  L. de Leij,et al.  Divalent cobalt as a label to study lymphocyte distribution using PET and SPECT. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[27]  C. Bordignon,et al.  Herpes simplex virus thymidine kinase gene transfer for controlled graft-versus-host disease and graft-versus-leukemia: clinical follow-up and improved new vectors. , 1998, Human gene therapy.

[28]  J. Humm,et al.  Imaging herpes virus thymidine kinase gene transfer and expression by positron emission tomography. , 1998, Cancer research.

[29]  A. Jacobs,et al.  Functional coexpression of HSV-1 thymidine kinase and green fluorescent protein: implications for noninvasive imaging of transgene expression. , 1999, Neoplasia.

[30]  S. Cherry,et al.  Imaging adenoviral-directed reporter gene expression in living animals with positron emission tomography. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[31]  R. Blasberg,et al.  Imaging brain tumor proliferative activity with [124I]iododeoxyuridine. , 2000, Cancer research.

[32]  R. Finn,et al.  Low energy cyclotron production and chemical separation of "no carrier added" iodine-124 from a reusable, enriched tellurium-124 dioxide/aluminum oxide solid solution target , 2000 .

[33]  Ralph Weissleder,et al.  Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells , 2000, Nature Biotechnology.

[34]  S. Larson,et al.  Imaging transgene expression with radionuclide imaging technologies. , 2000, Neoplasia.

[35]  M. Sadelain,et al.  Rapid selection of antigen-specific T lymphocytes by retroviral transduction. , 2000, Blood.

[36]  C. Contag,et al.  Adoptive Immunotherapy of Experimental Autoimmune Encephalomyelitis Via T Cell Delivery of the IL-12 p40 Subunit1 , 2001, The Journal of Immunology.

[37]  R Weissleder,et al.  Normal T-cell response and in vivo magnetic resonance imaging of T cells loaded with HIV transactivator-peptide-derived superparamagnetic nanoparticles. , 2001, Journal of immunological methods.

[38]  Craig W. Reynolds,et al.  Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft. , 2001, Blood.

[39]  J Humm,et al.  Imaging transcriptional regulation of p53-dependent genes with positron emission tomography in vivo , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[40]  C. Contag,et al.  Advancing animal models of neoplasia through in vivo bioluminescence imaging. , 2002, European journal of cancer.

[41]  Michael E. Phelps,et al.  Ex vivo cell labeling with 64Cu–pyruvaldehyde-bis(N4-methylthiosemicarbazone) for imaging cell trafficking in mice with positron-emission tomography , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[42]  M. Raffeld,et al.  Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes , 2002, Science.

[43]  B. Dréno,et al.  Randomized trial of adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma , 2002, Cancer Immunology, Immunotherapy.

[44]  Christopher H Contag,et al.  Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging. , 2003, Blood.